Roche Drug Reduces Skin Growths in Gene-Mutation Patients

A Roche Holding AG skin cancer drug reduced the size and number of growths in people genetically predisposed to the disease in a study published today, even as half the participants quit because of side effects.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.